Literature DB >> 8761268

Repetitive CMAPs: mechanisms of neural and synaptic genesis.

J G van Dijk1, G J Lammers, A R Wintzen, P C Molenaar.   

Abstract

Repetitive compound muscle action potentials (R-CMAPs) occur when a single nerve shock excites muscle fibers repeatedly. "Double discharges" are due to intramuscular nerve reexcitation. "Synaptic" R-CMAPs, due to excess acetylcholine in the neuromuscular synapse, can occur in congenital myasthenia, the slow-channel syndrome, and acetylcholinesterase inhibition. Secondary nerve excitation can reexcite muscle fibers. Synaptic R-CMAPs in a patient consisted of two discharges. The second diminished during repetitive stimulation and began 3.5-4.0 ms after the first, which is slightly longer than the synapse-muscle refractory period. Neural R-CMAPs, due to ectopic nerve activity, occur in neuromyotonia (NMT). R-CMAPs in a patient consisted of about 20 discharges at 200-300 Hz. Studies in healthy subjects showed that such trains represent added single CMAPs. Impulse frequency in the patient lied close to the threshold of refractoriness. Refractoriness of the synapse-muscle cell assembly determines the characteristics of R-CMAPs regardless of the primary cause.

Entities:  

Mesh:

Year:  1996        PMID: 8761268     DOI: 10.1002/(SICI)1097-4598(199609)19:9<1127::AID-MUS7>3.0.CO;2-1

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  7 in total

1.  Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.

Authors:  Andrew Hill; Peter Bergin; Fritha Hanning; Paul Thompson; Michael Findlay; Dragan Damianovich; Mark J McKeage
Journal:  BMC Cancer       Date:  2010-08-23       Impact factor: 4.430

2.  Repetitive compound muscle action potentials in electrophysiological diagnosis of congenital myasthenic syndromes: a case report and review of literature.

Authors:  R Shiva Kumar; Abraham Kuruvilla
Journal:  Ann Indian Acad Neurol       Date:  2010-04       Impact factor: 1.383

3.  Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage II and stage III colorectal cancer patients: results from a prospective, randomised, single-centre, pilot clinical trial.

Authors:  R X Zhang; Z H Lu; D S Wan; X J Wu; P R Ding; L H Kong; Z Z Pan; G Chen
Journal:  Int J Colorectal Dis       Date:  2012-06-05       Impact factor: 2.796

4.  Clinical Significance of Repetitive Compound Muscle Action Potentials in Patients with Myasthenia Gravis: A Predictor for Cholinergic Side Effects of Acetylcholinesterase Inhibitors.

Authors:  Hyo Eun Lee; Yool Hee Kim; Seung Min Kim; Ha Young Shin
Journal:  J Clin Neurol       Date:  2016-10       Impact factor: 3.077

5.  Prospective Hospital-Based Clinical and Electrophysiological Evaluation of Acute Organophosphate Poisoning.

Authors:  Karkal Ravishankar Naik; Aralikatte Onkarappa Saroja; Nagabushan Hesarur; Rekha Satish Patil
Journal:  Ann Indian Acad Neurol       Date:  2019 Jan-Mar       Impact factor: 1.383

6.  Myasthenia in acquired neuromyotonia.

Authors:  Jung-Ick Byun; Hye-Jin Moon; Yoon-Ho Hong
Journal:  J Clin Neurol       Date:  2014-01-06       Impact factor: 3.077

7.  Clinical and Electrophysiologic Responses to Acetylcholinesterase Inhibitors in MuSK-Antibody-Positive Myasthenia Gravis: Evidence for Cholinergic Neuromuscular Hyperactivity.

Authors:  Ha Young Shin; Hyung Jun Park; Hyo Eun Lee; Young-Chul Choi; Seung Min Kim
Journal:  J Clin Neurol       Date:  2014-04-23       Impact factor: 3.077

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.